EP0789565A4 - Prävention der hiv-infektion - Google Patents

Prävention der hiv-infektion

Info

Publication number
EP0789565A4
EP0789565A4 EP94930075A EP94930075A EP0789565A4 EP 0789565 A4 EP0789565 A4 EP 0789565A4 EP 94930075 A EP94930075 A EP 94930075A EP 94930075 A EP94930075 A EP 94930075A EP 0789565 A4 EP0789565 A4 EP 0789565A4
Authority
EP
European Patent Office
Prior art keywords
prevention
hiv infection
hiv
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94930075A
Other languages
English (en)
French (fr)
Other versions
EP0789565A1 (de
Inventor
Jess G Thoene
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0789565A1 publication Critical patent/EP0789565A1/de
Publication of EP0789565A4 publication Critical patent/EP0789565A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/02—Contraceptive devices; Pessaries; Applicators therefor for use by males
    • A61F6/04—Condoms, sheaths or the like, e.g. combined with devices protecting against contagion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP94930075A 1993-10-15 1994-10-13 Prävention der hiv-infektion Withdrawn EP0789565A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13669793A 1993-10-15 1993-10-15
US136697 1993-10-15
PCT/US1994/011393 WO1995010268A1 (en) 1993-10-15 1994-10-13 Prevention of hiv infection

Publications (2)

Publication Number Publication Date
EP0789565A1 EP0789565A1 (de) 1997-08-20
EP0789565A4 true EP0789565A4 (de) 1999-03-24

Family

ID=22473963

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94930075A Withdrawn EP0789565A4 (de) 1993-10-15 1994-10-13 Prävention der hiv-infektion

Country Status (5)

Country Link
US (1) US5646189A (de)
EP (1) EP0789565A4 (de)
AU (1) AU7931094A (de)
CA (1) CA2173964A1 (de)
WO (1) WO1995010268A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1177594C (zh) * 1996-05-09 2004-12-01 传染病研究股份有限公司 预防治疗粘膜皮肤各种感染 (特别是包括人类免疫缺陷病毒的性传播性疾病 )、炎症、赘生物或其他类型疾病的方法和制剂
JPH09323935A (ja) * 1996-05-31 1997-12-16 Sangi Co Ltd 抗ウイルス剤、その製造方法及びその応用
JP3012923B2 (ja) * 1998-01-26 2000-02-28 新潟大学長 Ｃａｇリピート病の治療薬
FR2794122B1 (fr) * 1999-05-27 2001-09-07 Centre Nat Rech Scient Nouveaux antioxydants, procedes de preparation et utilisations
WO2004105662A1 (en) * 2003-05-23 2004-12-09 Program For Appropriate Technology In Health Microbicidal compositions and methods of use
AR057623A1 (es) 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
US20100247564A1 (en) * 2007-05-24 2010-09-30 David Yue-Wei Lee Methods and compositions for the use of sargassum fusiforme for the inhibition of hiv-1 infection
EP4125839A4 (de) * 2020-04-01 2024-04-24 Thiogenesis Therapeutics, Inc. Cysteaminvorläuferverbindungen zur behandlung von betacoronavirusinfektionen
EP4157247A1 (de) * 2020-05-25 2023-04-05 Novabiotics Limited Antivirale therapie

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2269346A1 (de) * 1974-05-02 1975-11-28 Istituto Chemioterapico
EP0080879A2 (de) * 1981-11-28 1983-06-08 Sunstar Kabushiki Kaisha Stabilisiertes Interferon enthaltende pharmazeutische Zusammensetzung
GB2177917A (en) * 1985-07-09 1987-02-04 Aws Shakir Mustafa Salim Dermatologically active substances
WO1993006832A1 (en) * 1991-09-30 1993-04-15 Thoene Jess G Method of treating hiv infection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892824A (en) * 1968-12-16 1975-07-01 Southern Res Inst S-{107 -({107 -aminoalkylamino)alkyl dihydrogen phosphorothioates
CA1157774A (en) * 1980-07-30 1983-11-29 Anthony Cerami Method for the reduction of mucin viscosity
US4885285A (en) * 1984-09-13 1989-12-05 Ciba-Geigy Corporation Phosphorus compounds, processes for their manufacture, and their use
DE3684514D1 (de) * 1985-06-08 1992-04-30 Asta Medica Ag Verwendung von penicillamin zur behandlung von immunmangelkrankheiten.
CA1339256C (en) * 1989-01-26 1997-08-12 Wulf Droge Treatment of diseases associated with hiv-infections
WO1990014007A1 (en) * 1989-05-24 1990-11-29 U.S. Bioscience Method for protection from azt side effects and toxicity
US5554655A (en) * 1991-09-30 1996-09-10 Jess G. Thoene Method of treating HIV infection
WO1994004185A2 (en) * 1992-08-19 1994-03-03 Trustees Of Boston University Method of inhibiting reduction of disulfide bonds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2269346A1 (de) * 1974-05-02 1975-11-28 Istituto Chemioterapico
EP0080879A2 (de) * 1981-11-28 1983-06-08 Sunstar Kabushiki Kaisha Stabilisiertes Interferon enthaltende pharmazeutische Zusammensetzung
GB2177917A (en) * 1985-07-09 1987-02-04 Aws Shakir Mustafa Salim Dermatologically active substances
WO1993006832A1 (en) * 1991-09-30 1993-04-15 Thoene Jess G Method of treating hiv infection

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
A. BERGAMINI ET AL.: "CYSTAMINE POTENTLY SUPPRESSES IN VITRO HIV REPLICATION IN ACUTELY AND CHRONICALLY INFECTED HUMAN CELLS", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 93, no. 5, May 1994 (1994-05-01), pages 2251 - 2257, XP002079345 *
CHEMICAL ABSTRACTS, vol. 67, no. 9, 28 August 1967, Columbus, Ohio, US; abstract no. 40803, F. TATSURO: "RADIATION PROTECTIVE EFFECTS OF LOCAL ADMINISTERED CYSTEAMINE" XP002079353 *
CHEMICAL ABSTRACTS, vol. 80, no. 8, 25 February 1974, Columbus, Ohio, US; abstract no. 40987, I.A. MURAV'EV ET AL.: "EXPERIMENTAL STUDIES ON CYSTEAMINE IN RECTAL SUPPOSITORIES" XP002079355 *
CHEMICAL ABSTRACTS, vol. 81, no. 16, 21 October 1974, Columbus, Ohio, US; abstract no. 96382, G.E. BATRAK ET AL.: "RECTAL ADMINISTRATION OF CYSTAMINE HYDROCHLORIDE" XP002079354 *
D.G. BAKER ET AL.: "PROTECTION OF THE SKIN OF MICE AGAINST IRRADIATION WITH CYCLOTRON-ACCELERATED HELIUM IONS BY 2-MERCAPTOETHYLAMINE", ACTA RADIOLOGICA THERAPY PHYSICS BIOLOGY, vol. 14, no. 6, 1975, pages 561 - 571, XP002079351 *
FARM. ZH., vol. 28, no. 5, 1973, pages 54 - 56 *
FARMATSIYA, vol. 23, no. 2, 1974, MOSCOW, pages 30 - 32 *
FUKUOKEU-IGAKU-ZASSHI, vol. 56, no. 10, 1965, pages 930 - 944 *
G. GUNNARSSON ET AL.: "EFFECT OF COMBINATIONS OF CYSTEAMINE (MERCAPTOETHYLAMINE) AND NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS ON HIV-1 REPLICATION IN VITRO", ABSTRACTS OF THE INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 34, October 1994 (1994-10-01), pages 93, XP002079346 *
G. GUNNARSSON ET AL.: "EFFECT OF CYSTEAMINE (MERCAPTOETHYLAMINE, MEA) ON HIV-1 REPLICATION IN VITRO", IXTH INTERNATIONAL CONFERENCE ON AIDS, June 1993 (1993-06-01), BERLIN, GERMANY, pages 230, XP002079348 *
H.J. ANTONE ET AL.: "CHEMICAL PROTECTION OF MAMMALIAN ORAL MUCOSA EXPOSED TO DAILY LOCAL RADIATION", JOURNAL OF DENTAL RESEARCH, vol. 52, no. 5, 1973, pages 1153, XP002079352 *
J.G. THOENE: "IN VITRO EFFECTIVENESS OF AMINOTHIOLS AND DISULFIDES AGAINST HIV-I", CLINICAL RESEARCH, vol. 40, no. 2, 1992, pages 246A, XP002079347 *
L. DARCIS ET AL.: "APPLICATION VAGINALE DE CYSTAMINE ET RADIOPROTECTION LOCALE", EXPERIENTIA, vol. 13, no. 6, 1957, pages 242 - 243, XP002079349 *
L. DARCIS ET AL.: "DE L'ACTION PROTECTRICE EXERCEE SUR LA MUQUEUSE RECTALE PAR LA CYSTEAMINE ADMINISTREE PAR VOIE GENERALE ET PAR LA CYSTAMINE ADMINISTREE PAR VOIE INTRARECTALE", EXPERIENTIA, vol. 14, no. 1, 1958, pages 18 - 21, XP002079350 *
See also references of WO9510268A1 *

Also Published As

Publication number Publication date
US5646189A (en) 1997-07-08
WO1995010268A1 (en) 1995-04-20
EP0789565A1 (de) 1997-08-20
CA2173964A1 (en) 1995-04-20
AU7931094A (en) 1995-05-04

Similar Documents

Publication Publication Date Title
AU7557494A (en) Infection resistant medical devices
ZA9610139B (en) Treatment of the cns effects of hiv
AU7973994A (en) Combination therapy for hiv infection
AU1067599A (en) Peptide compositions for the treatment and prevention of hiv infection
NZ307494A (en) Lymphokine capable of inhibiting immunodeficiency viruses
GB9304746D0 (en) Treatment of viral infections
EP0789565A4 (de) Prävention der hiv-infektion
AU7131991A (en) Hiv protease inhibiting agents
ZA925305B (en) Inhibition of non-CD4 midiated HIV infection.
GR3026571T3 (en) Preparation of 2-H-heptafluoropropane.
HRP960045B1 (en) Combination therapy for hiv infection
AU2473695A (en) Method of slowing the progression of hiv infection
PL317876A1 (en) Combined treatment of hiv infections
ZA944577B (en) Preparation of aminopropionitriles
GB2284739B (en) Processing of whelks
GB2275266A8 (en) Preparation of 2-methyl-3-aminobenzotrifluoride
AU1389897A (en) Use of chemokines for the treatment and prevention of hiv infection
IL113846A0 (en) Post exposure prevention of hiv
OA09507A (en) Compositions and methods for treating or preventing AIDS ARC and HIV infection
ZA954426B (en) Post-exposure prevention of HIV
GB9307702D0 (en) Preparation of co-polymers
ZA938617B (en) Preparation of co-polymers
GB9304675D0 (en) Prophylaxis for hiv infection
AU4041493A (en) Shuttlecock of various uses
AU5095996A (en) Interferon-gamma treatment of HLA-DR-associated immunodeficiency

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960510

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19990205

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19991208

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20011108